Everything below concerns MOD GRF 1-29. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-12-26. Where a claim depends on a specific study, the study is described rather than over-claimed.
CJC-1295 belongs to a family of synthetic peptides modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound is built from the first twenty-nine amino acids of the natural human sequence, a fragment that retains full receptor binding capacity. Native growth hormone-releasing hormone is degraded quickly in circulation, so the fragment alone has limited practical value. Early work therefore focused on chemical modifications that preserve receptor binding while slowing enzymatic breakdown. The result is a molecule described in the literature as a long-acting analog of the natural hormone.
Two forms circulate under the CJC-1295 name, and they differ by a single appended group. The version without a drug affinity complex carries four substitutions along the peptide chain, including a D-alanine near the amino terminus and replacements at three other positions. These changes block the enzyme dipeptidyl peptidase IV and remove a methionine residue that is prone to oxidation. The modified fragment is frequently labeled MOD GRF 1-29. Naming conventions are inconsistent across informal sources, which is a common source of confusion.
The dividing feature between the two forms is a maleimide-based drug affinity complex, abbreviated DAC. In the DAC-bearing version, a linker attaches the peptide to serum albumin after administration, and that association slows removal from plasma. The version lacking DAC appears in catalogs as MOD GRF(1-29) or tetrasubstituted GRF(1-29). Because informal writing treats both as one item, comparisons drawn from such sources routinely blend measurements taken from two molecules with substantially different behavior.
Four amino acid substitutions separate the modified backbone from the parent GRF(1-29) sequence. These changes reduce recognition by dipeptidyl peptidase IV and related proteases, extending the interval before degradation. Development work in this area sought longer-acting GHRH analogs for endocrine investigation. Published descriptions treat the substitution set as a defining property of the core sequence, while the albumin-binding linker is described separately as an optional addition to that same backbone.
CJC-1295 is a synthetic peptide analog of growth hormone-releasing hormone, constructed on the 29-amino-acid fragment designated GRF(1-29). The name began as an internal development code during the 1990s and later spread through research supply catalogs and discussion forums. The molecule does not occur in nature; its sequence is engineered rather than isolated from tissue. Two related compounds are sold under this single label, and they differ by one appended chemical group that strongly influences how long the peptide remains in circulation.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Analog of growth hormone-releasing hormone |
| Chain length | 29 amino acids | Based on the GRF(1-29) fragment |
| Appearance | White to off-white lyophilized powder | Common research supply form |
| Solubility | Soluble in water and aqueous buffers | Powder requires reconstitution before use |
| Typical storage | −20 °C or below | Kept away from light and moisture |
Studies in this area generally track growth hormone pulses, insulin-like growth factor 1 concentrations, and occasionally body composition endpoints. Most published human data come from early, small trials, and questions about long-term effects remain open. Whether repeated exposure alters pituitary responsiveness over time is not settled. Analytical work relies on immunoassays for the hormones and on mass spectrometry for the peptide itself, because the two measurements answer different questions.
Binding of the peptide to the growth hormone-releasing hormone receptor on pituitary somatotrophs triggers a G protein coupled cascade that raises cyclic AMP and opens calcium channels. The result is greater secretion of growth hormone into the bloodstream. Because the peptide acts at the same receptor as the natural hypothalamic hormone, its effect is amplified pulse size rather than an entirely separate release pathway. Receptor binding alone does not determine the response, since somatostatin tone and other inputs modulate the final output.
Analytical confirmation usually relies on reversed-phase high-performance liquid chromatography for purity and on liquid chromatography coupled to mass spectrometry for identity. Mass data reveal the expected molecular mass and can flag truncated or oxidized species. Amino acid analysis and peptide mapping provide sequence-level verification. Immunoassays are used in some biological matrices, but antibodies raised against one releasing-hormone analog may cross-react with another. Reported purity figures depend heavily on the method used, so comparisons between suppliers require matching the analytical approach.
The two variants differ dramatically in how long they persist in circulation. The form lacking the albumin-binding group has a plasma half-life measured in tens of minutes, comparable to the natural hormone fragment. The version carrying the drug affinity complex binds albumin and shows a half-life of roughly six to eight days in human studies. That figure comes from small trials that tracked hormone levels over extended periods. The physiological consequences of sustained versus pulsatile stimulation are still debated and the literature does not settle the point.
Clearance profiles diverge sharply between the two versions. The albumin-binding molecule stays in plasma for several days, whereas the unmodified analog is largely gone within about half an hour in reported work. Cleavage by dipeptidyl peptidase IV is a major contributor to the short life of the unmodified sequence. These gaps mean the two versions cannot be substituted for each other in study design or in reading results side by side.
Reports on this compound commonly follow serum growth hormone and insulin-like growth factor 1 across defined time windows. Protocols differ in sampling frequency, assay platform, and participant characteristics, which makes direct comparison between publications difficult. Some work focuses on pulsatile release patterns instead of average concentrations. Whether repeated exposure alters endogenous hormone rhythms over long periods remains an open question, and the formal literature is thinner than the volume of informal commentary implies.
Once in circulation, the peptide binds the growth hormone-releasing hormone receptor displayed on pituitary somatotroph cells. Receptor activation couples to Gs proteins, elevates intracellular cyclic AMP, and drives protein kinase A signaling inside the cell. That cascade increases discharge of growth hormone into the bloodstream. The analog therefore operates through a receptor pathway that already exists for the body's own releasing hormone, rather than through an engineered artificial target.
Second, insulin is expected to increase muscle mass by preventing the breakdown of muscle protein when consumed along with a high carb-protein diet. Although a limited number of studies do suggest that insulin medication can be abused as a pharmacological treatment to boost strength and performance in young, healthy people or athletes, a recent assessment of the research argues that this is only applicable to a small group of "drug-naïve" individuals.
==== August 2008 ==== Nezavisimaya Gazeta reported in June 2008 that when Chechen peacekeepers from Vostok Battalion began serving in South Ossetia in the autumn of 2007, they began arresting armed people with fake peacekeeping IDs. However, the Chechens were soon ordered to cease the arrest of the impostors and armed people with unknown affiliations were now freely roaming South Ossetia. On 4 August 2008, Life.ru reported that after the end of the "Kavkaz 2008" exercises, the paratroopers from Pskov remained to occupy the key positions on the Roki and Mamison passes on the border. Several battalions of 58th Army were deployed close to the border and the South Ossetian sources told the newspaper that the deployment of troops began on the night of 2–3 August 2008. Life.ru reported, "The deployment of the Russian military hardware near the Roki Tunnel will allow as soon as possible to move troops to help the peacemaking forces." On 6 August 2008, OsRadio reported that the volunteers were also arriving in Tskhinvali from Moscow. On 26 September 2008, Trud reported on the special battalion Vostok. One member of the battalion Khamzat said, "See what the "Red Star" wrote about us: Volunteers from neighboring republics arrive in South Ossetia. So we are volunteers?!" Khamzat added, "We are the regular subunit of 291-th Regiment of 42nd Guards Motor Rifle Division of the North Caucasus Military District. And we only act on orders." On 8 August 2008, Nezavisimaya Gazeta published an article by journalist who had spent previous three days in Chechnya.
=== General and cited references === Carnegie Library of Pittsburgh. Science and Technology Department. The Handy Science Answer Book. Pittsburgh: The Carnegie Library, 1997. ISBN 978-0-7876-1013-5. Perham, Nick; Moore, Simon C.; Shepherd, Jonathan; Cusens, Bryany (2007). "Identifying drunkenness in the night-time economy". Addiction. 102 (3): 377–80. doi:10.1111/j.1360-0443.2006.01699.x. PMID 17298644. Taylor, L., and S. Oberman. Drunk Driving Defense, 6th edition. New York: Aspen Law and Business, 2006. ISBN 978-0-7355-5429-0.
=== Bleeding esophageal varices === Octreotide is often given as an infusion for management of acute hemorrhage from esophageal varices in liver cirrhosis on the basis that it reduces portal venous pressure, though current evidence suggests that this effect is transient and does not improve survival.
Sources: en.wikipedia.org
The main difference between Minds and other extremely powerful artificial intelligences in fiction is that they are highly humanistic and benevolent. They are so both by design, and by their shared culture. They are often even rather eccentric. Yet, by and large, they show no wish to supplant or dominate their erstwhile creators. On the other hand, it can also be argued that to the Minds, the human-like members of the Culture amount to little more than pets, whose wants are followed on a Mind's whim. Within the Series, this dynamic is played on more than once. In 'Excession', it is also played on to put a Mind in its place – in the mythology, a Mind is not thought to be a god, still, but an artificial intelligence capable of surprise, and even fear.
David G. Armstrong (born February 18, 1969) is an American podiatric surgeon and academic known for his work in diabetic foot care, wound healing, and limb preservation. He is a Distinguished Professor of Surgery and Neurological Surgery at the University of Southern California (USC), where he directs the university's Center to Stream Healthcare in Place (C2SHiP), a National Science Foundation–funded initiative focused on advancing home-based health technologies and care models. Armstrong is the founding president of the American Limb Preservation Society (ALPS) and co-founder and co-chair of the International Diabetic Foot Conference (DFCon), the largest annual international symposium on the diabetic foot in the world. He also co-founded the Southwestern Academic Limb Salvage Alliance (SALSA) and has contributed to the development of interdisciplinary strategies for managing chronic limb-threatening ischemia and preventing diabetes-related amputations.
This also strongly suggests that the island of stability (for spherical nuclei) is not completely isolated from the region of stable nuclei, but rather that both regions are instead linked through an isthmus of relatively stable deformed nuclei.
During 1973–2013, Khavinson et al., extracted from various organs over 20 complexes of physiologically active peptides, as well as 15 others synthesized from amino acids, (di-, tri-, tetrapeptides), all being covered by patents in many countries including the US, Canada, Australia, Europe, Japan, Korea, Israel, etc. After many years of experimental and clinical studies, six medicinal peptide preparations were permitted for medical use in the USSR, Russia, and afterward in the CIS countries. They were primarily to be used by the military medical service. These are ‘Thymalin’- a preparation of the thymus, being a cellular immunity regulator; ‘Epithalamin’ — a preparation from the pineal gland — regulator of the endocrine system, which restores melatonin, (with no analogues worldwide) ‘Cortexin’ — a preparation from the cerebral cortex, brain function regulator; ‘Prostatilen’ or ‘Samprost’ or ‘Vitaprost’ — a preparation from the prostate gland, regulator of prostate function; ‘Retinalamin’ — a preparation from the retina, partially restores functions of the retina in case of laser lesions and degenerative diseases, has no analogues worldwide; ‘Thymogen’ — a dipeptide EW, being first extracted from ‘Thymalin’, then synthesized from amino acids, regulates immunity. These medicinal peptide preparations were first used to restore immune functions of the brain, endocrine system, retina, etc.
https://www.nobelprize.org/prizes/medicine/2023/press-release/ 2025: South African-born physicist and space scientist Michele Dougherty is appointed Astronomer Royal for the United Kingdom, becoming the first woman appointed to the role in its 350-year history. 2025: American biologist Mary E. Brunkow receives the Nobel Prize in Physiology or Medicine for her studies of the FOXP3 gene, which was significant to future studies of peripheral immune tolerance. She shared this award with immunologists Fred Ramsdell and Shimon Sakaguchi. 2026: Kazakhstan launches its first all female Space Isolation Experiment, SANA-1, at the National Space Center.
Sources: en.wikipedia.org
No. It is a laboratory-synthesized analog built on a fragment of the natural hormone. The natural peptide is shorter-lived and lacks the stabilizing substitutions found in the synthetic version.
DAC stands for drug affinity complex, a chemical group that binds the peptide to serum albumin. The binding slows clearance and lengthens the time the molecule stays in plasma compared with the unmodified analog.
Because two distinct molecules are discussed under one informal label. The albumin-binding version clears over several days, while the form without that group clears within roughly half an hour. Mixing results from both creates inconsistent figures.
Reported values cluster in the range of several days, reflecting slow release from the albumin complex. Estimates differ across species and assay platforms. The figure describes circulation time in study settings rather than a fixed property.